A comprehensive physiologically based pharmacokinetic (PBPK) model for nicotine in humans from using nicotine-containing products with different routes of …
AA Rostami, JL Campbell, YB Pithawalla… - Scientific Reports, 2022 - nature.com
Physiologically based pharmacokinetic (PBPK) modeling can be a useful tool for
characterizing nicotine pharmacokinetics (PK) from use of tobacco products. We expand a …
characterizing nicotine pharmacokinetics (PK) from use of tobacco products. We expand a …
Comprehensive parent–metabolite PBPK/PD modeling insights into nicotine replacement therapy strategies
Background Nicotine, the pharmacologically active substance in both tobacco and many
electronic cigarette (e-cigarette) liquids, is responsible for the addiction that sustains …
electronic cigarette (e-cigarette) liquids, is responsible for the addiction that sustains …
[HTML][HTML] Application of open-source PBPK models in rat-to-human pharmacokinetic extrapolation of oral nicotine exposure
Abstract Physiologically Based Pharmacokinetic (PBPK) models are often developed using
animal data and applied to predict chemical movement and concentration in humans …
animal data and applied to predict chemical movement and concentration in humans …
Nicotine population pharmacokinetics in healthy adult smokers: a retrospective analysis
M Marchand, P Brossard, H Merdjan, N Lama… - European journal of …, 2017 - Springer
Abstract Background and Objective Characterizing nicotine pharmacokinetics is challenging
in the presence of background exposure. We performed a combined retrospective …
in the presence of background exposure. We performed a combined retrospective …
[HTML][HTML] Deconvolution of systemic pharmacokinetics predicts inhaled aerosol dosimetry of nicotine
Absorption of inhaled compounds can occur from multiple sites based on upper and lower
respiratory tract deposition, and clearance mechanisms leading to differential local and …
respiratory tract deposition, and clearance mechanisms leading to differential local and …
Nicotine population pharmacokinetics in healthy smokers after intravenous, oral, buccal and transdermal administration
PO Olsson Gisleskog, JJ Perez Ruixo, Å Westin… - Clinical …, 2021 - Springer
Background In 4 decades, numerous nicotine replacement therapy products have been
developed. Population pharmacokinetic models can support exposure–response modeling …
developed. Population pharmacokinetic models can support exposure–response modeling …
[HTML][HTML] Plasma protein binding and tissue retention kinetics influence the rate and extent of nicotine delivery to the brain
AR Kolli - Toxicology Letters, 2023 - Elsevier
Nicotine from inhaled combustible cigarette smoke is delivered rapidly to the brain, and
sufficient unbound nicotine concentrations exert pharmacological effects. In addition to …
sufficient unbound nicotine concentrations exert pharmacological effects. In addition to …
A multi-route model of nicotine–cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans
JG Teeguarden, CJ Housand, JN Smith… - Regulatory Toxicology …, 2013 - Elsevier
The pharmacokinetics of nicotine, the pharmacologically active alkaloid in tobacco
responsible for addiction, are well characterized in humans. We developed a physiologically …
responsible for addiction, are well characterized in humans. We developed a physiologically …
Respirable aerosol exposures of nicotine dry powder formulations to in vitro, ex vivo, and in vivo pre-clinical models demonstrate consistency of pharmacokinetic …
D Sciuscio, J Hoeng, MC Peitsch… - Inhalation …, 2019 - Taylor & Francis
Background: Nicotine, because of its volatility, has a complex dosimetry following inhalation
as a vapor/aerosol mix. To better control the dosimetry, nicotine could be formulated with a …
as a vapor/aerosol mix. To better control the dosimetry, nicotine could be formulated with a …
A physiologically based pharmacokinetic model for nicotine and cotinine in man
DE Robinson, NJ Balter, SL Schwartz - Journal of pharmacokinetics and …, 1992 - Springer
Physiologically based pharmacokinetic (PBPK) models have been developed describing the
disposition kinetics of nicotine and its major metabolite, cotinine, in man. Separate 9 …
disposition kinetics of nicotine and its major metabolite, cotinine, in man. Separate 9 …